This is the authors' abstract. We don't add key points for this paper.
Hyperspectral imaging (HSI) with rich spectral and spatial information holds potential for applications ranging from remote sensing to biomedicine. However, charge-coupled device (CCD) detectors used in conventional HSI systems suffer from inferior and unbalanced responsivity in the visible region, which is not a perfect choice for high-performance visible HSI. That is, conventional Si-based CCDs exhibit poor responsivity at short wavelengths (e.g., 400–600 nm) compared with that at longer wavelengths due to the nature of the indirect bandgap in silicon of around 1.1 eV. To solve this challenge, we introduce a CsPbBr 3 perovskite layer to shape the spectrum of a Si/PEDOT:PSS heterojunction photodetector (PD), resulting in a fabricated Si- CsPbBr 3 hybrid PD with enhanced responsivity at 400–600 nm. This results in an approximately flat spectral responsivity curve in the visible region (400–800 nm). Therefore, the stable Si − CsPbBr 3 hybrid PD with a flat spectrum overcomes the shortcomings of traditional Si-based PDs and makes it more suitable for HSI. Further, we set up a first perovskite HSI system with high spectrum resolution and demonstrate potential applications for tumor detection and tissue identification. We believe that this perovskite optimization can be integrated into modern CCD, thus becoming a step in future CCD fabrication processes, which is a milestone for high-performance HSI systems.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: